Demographic, antipsychotic treatment, anticholinergic drug treatment and central nervous system collection characteristics
| Cortex and thalamus; mean ± SEM* | Hippocampus; mean ± SEM* | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Controls (n = 12) | Schizophrenia (n = 24) | p value | Non-MRDS (n = 12) | MRDS (n = 12) | p value | F2,33 | Controls (n = 5) | Schizophrenia (n = 13) | p value | Non-MRDS (n = 7) | MRDS (n = 6) | p value | F2,15 |
| Sex, M/F, n | 9/3 | 18/6 | > 0.99 | 9/3 | 9/3 | > 0.99 | — | 4/1 | 9/4 | > 0.99 | 5/2 | 4/2 | 0.88 | — |
| Age, yr | 48 ± 5.5 | 48 ± 3.4 | 0.95 | 48 ± 4.4 | 49 ± 5.3 | 0.99 | 0.007 | 29 ± 4.3 | 49 ± 4.2 | 0.02 | 47 ± 5.2 | 51 ± 7.3 | 0.06 | 3.05 |
| PMI, h | 46 ± 4.4 | 39 ± 2.5 | 0.09 | 39 ± 3.7 | 40 ± 3.5 | 0.2 | 1.5 | 45 ± 7 | 37 ± 3.9 | 0.33 | 37 ± 4.8 | 39 ± 7 | 0.62 | 0.48 |
| pH | 6.34 ± 0.09 | 6.27 ± 0.04 | 0.15 | 6.31 ± 0.05 | 6.22 ± 0.06 | 0.23 | 1.53 | 6.21 ± 0.12 | 6.29 ± 0.05 | 0.5 | 6.32 ± 0.07 | 6.25 ± 0.07 | 0.67 | 0.41 |
| Suicide,† Y/N, n | 0/12 | 7/17 | — | 3/9 | 4/8 | 0.99 | — | — | 4/9 | — | 2/5 | 2/4 | 0.99 | — |
| DI, yr | — | 20.5 ± 3.1 | — | 21 ± 3.7 | 20 ± 5.2 | 0.98 | — | — | 20 ± 4.1 | — | 19 ± 4.5 | 21 ± 7.6 | 0.93 | — |
| FRADD‡ | — | 542 ± 109 | — | 638 ± 172 | 446 ± 136 | 0.39 | — | — | 718 ± 183 | — | 783 ± 265 | 640 ± 275 | 0.71 | — |
| Anticholinergic drug exposure,§ | 0/12 | 11/13 | — | 5/7 | 6/6 | > 0.99 | — | 0/5 | 6/7 | — | 2/5 | 4/2 | 0.29 | — |
DI = duration of illness; F = female; FRADD = final recorded antipsychotic drug dose; M = male; MRDS = muscarinic receptor deficit form of schizophrenia; PMI = postmortem interval; SEM = standard error of the mean.
↵* Unless otherwise indicated.
↵† Listed as cause of death by coroner.
↵‡ Shown as mg chlorpromazine equivalents per day.
↵§ Recorded exposure anywhere in case history.